Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor

Rhea-AI Summary

Beta Bionics (BBNX) announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's upcoming dual glucose-ketone sensor in the U.S. The iLet system is notable as the first and only automated insulin delivery system making 100% automated dosing decisions, eliminating the need for carb counting or manual insulin calculations. The system currently works with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and this new integration represents an expansion of the existing partnership between the companies. The integration aims to enhance real-time decision-making support for diabetes patients once Abbott's new sensor becomes commercially available.

Positive

• First and only automated insulin delivery system with 100% automated dosing decisions
• Eliminates need for carb counting and manual insulin calculations
• Strategic partnership with Abbott strengthens market position
• Expanding product compatibility with future innovative technology

Negative

• Integration timeline dependent on Abbott's future sensor commercial availability
• Users must still maintain carb awareness despite automated system

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S.

The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. With the iLet, people living with diabetes can achieve excellent clinical outcomes without the burden of carb counting* or manual insulin correction calculations. The system currently supports Abbott’s FreeStyle Libre^® 3 Plus continuous glucose monitoring sensor, and this future design further extends the collaboration between Beta Bionics and Abbott, reinforcing their shared commitment to bringing cutting-edge diabetes solutions to the market.

“This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,” said Sean Saint, President and CEO of Beta Bionics. “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available.”

*User must be carb aware

About Beta Bionics
Beta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet^® Bionic Pancreas—the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. Designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes, the iLet sets a new standard in diabetes care. For more information, visit www.betabionics.com.

Important Safety Information
Product for prescription only. For important safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

Investor Relations Contact:
ir@betabionics.com

Media and Public Relations Contact:
media@betabionics.com

FAQ

What is the key feature of Beta Bionics' (BBNX) iLet Bionic Pancreas system?

The iLet is the first and only automated insulin delivery system that makes 100% of insulin dosing decisions automatically, eliminating the need for carb counting and manual insulin calculations.

Which glucose monitoring system is currently compatible with Beta Bionics' iLet system?

The iLet system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor.

What new integration is Beta Bionics (BBNX) planning for the iLet system?

Beta Bionics plans to integrate the iLet Bionic Pancreas with Abbott's future dual glucose-ketone sensor in the U.S.

Who is the CEO of Beta Bionics?

Sean Saint serves as the President and CEO of Beta Bionics.

Does the Beta Bionics iLet system require carb counting?

The system eliminates the need for carb counting, though users must still remain carb aware.